GlassScriptPhysician profile
Kelsey Ward
NPI 1720448616
$2,154.44
in general payments reported to CMS, 2019-2025
19 companies · $846 in 2025
The $846 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.99 · 2022: $601 · 2023: $428 · 2024: $205 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410 · Education: $69.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.48 |
| Education | $69.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $424.91 | 2021-2025 | Niktimvo, Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $346.37 | 2022-2024 | Livtencity, Iclusig |
| Sanofi-Aventis U.S. LLC | $270.17 | 2022-2025 | |
| La Jolla Pharmaceutical Company | $261.20 | 2025 | Xacduro |
| Amgen INC. | $145.15 | 2022 | |
| Melinta Therapeutics, LLC | $125.00 | 2024 | Rezzayo |
| Kite Pharma, INC. | $116.27 | 2023 | Yescarta |
| Medline Industries LP | $71.68 | 2025 | |
| Legend Biotech USA INC. | $69.05 | 2023-2025 | Carvykti |
| Stemline Therapeutics INC. | $62.08 | 2025 | Elzonris |
| Abbvie INC. | $57.97 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $54.97 | 2023-2025 | Prevymis, Dificid, Zerbaxa |
| Celgene Corporation | $31.91 | 2022-2023 | Onureg |
| Genmab U.S., INC. | $30.16 | 2023 | Epkinly |
| Daiichi Sankyo INC. | $21.45 | 2025 | Vanflyta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $19.53 | 2023 | Fetroja |
| Servier Pharmaceuticals LLC | $18.18 | 2025 | |
| Pfizer INC. | $14.40 | 2023 | |
| Astellas Pharma US INC | $13.99 | 2023 | Xospata |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.